Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., announced its decision to voluntarily withdraw OCALIVA® (obeticholic acid) from the US market for the treatment of primary biliary cholangitis (PBC), a rare, progressive liver disease.
Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or call 1-844-782-4278. Patients should talk to their healthcare professionals and may also contact Intercept's Patient Support Services (Interconnect) at 1-844-622-4278.
For all other inquiries please visit: https://www.interceptpharma.com/
Please click here for Full Prescribing Information and Medication Guide for OCALIVA.
Acknowledge